Loading
A phase 1/2 trial of PM8002 in advanced solid tumours, run by BioNTech SE, now recruiting.
A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07147348 by BioNTech SE, with 375 participants planned, started 2025-08-27 and due to reach its primary completion in 2027-11. Interventions recorded: BNT3212 and Pumitamig.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares PM8002, BioNTech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares PM8002, BioNTech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares BioNTech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares BioNTech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares BioNTech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/